| The principal aim of lipid-lowering therapy in Homozygous familial hypercholesterolaemia (HoFH) is to avert or delay the onset of atherosclerotic cardiovascular disease (ASCVD). |
| The effect of lomitapide on markers of subclinical atherosclerosis has not been studied in clinical trials |
| The present case series examines changes in carotid intima-media thickness (CIMT) in 14 patients receiving lomitapide in the normal course of care. |
| Lomitapide substantially reduced Low-density lipoprotein cholesterol (LDL-C) levels in the patients with HoFH and resulted in stabilisation and/or regression of CIMT |
| Lomitapide may have the potential to delay or avert ASCVD progression in patients with HoFH |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.